<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12331">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02946411</url>
  </required_header>
  <id_info>
    <org_study_id>R-2016-785.080</org_study_id>
    <nct_id>NCT02946411</nct_id>
  </id_info>
  <brief_title>Correlation of Hospital Stay Length With the Glucose Levels After Cardiac Surgery</brief_title>
  <official_title>Correlation of Hospital Stay Length With the Glucose Measured Continuously Levels After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinaci贸n de Investigaci贸n en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinaci贸n de Investigaci贸n en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to test if there is any correlation between the glucose levels in the
      postoperatory period and the length of hospital stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The stress hyperglycemia commonly observed in the postoperatory period, there have been
      several studies to assess if there is benefit of having a strict glucose control or not.

      This study will assess if there is correlation between the glucose levels measured
      continuously with the length of the stay in the hospital.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>5 days</time_frame>
    <description>Glucose will be continuously monitored for 5 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>[Days] Within the first 20 days after surgery</time_frame>
    <description>The days that the patient remains in the hospital after the surgery.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Stress Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>The glucose of 48 patients will be measured during 5 days after cardiac surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac surgery</intervention_name>
    <description>Glucose level will be measured after cardiac surgery.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a programmed cardiac surgery
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physical status classification of the American Society of Anesthesiologists (ASA)
             II-IV

          -  Patients programmed for cardiac surgery

          -  Any body mass index

        Exclusion Criteria:

          -  Pregnant women

          -  Chronic Kidney Disease (CKD) Stage 2 or higher
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Gallardo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Gallardo, Dr.</last_name>
    <phone>5556276900</phone>
    <phone_ext>22154</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Sanchez, Dr.</last_name>
    <phone>5556276900</phone>
    <phone_ext>22154</phone_ext>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>October 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
